Alnylam Steps Into Obesity Drug Race With New ALN-2232 Trial

Alnylam Pharmaceuticals (ALNY) announced an update on their ongoing clinical study.

Alnylam Pharmaceuticals is running a Phase 1/2 trial called “A Study to Evaluate ALN-2232 in Participants With Obesity.” The goal is to test safety and early effects of ALN-2232 alone and together with tirzepatide in adults with obesity, a fast growing market where new drug classes can shift the outlook for the whole sector.

The study tests ALN-2232, an injectable RNA-based drug, given under the skin to help with weight management. It is used alone in some groups and started at the same time as tirzepatide in others, aiming to see if the combo can boost weight loss beyond current options.

The trial is interventional and randomized, so participants are assigned by chance to ALN-2232, tirzepatide, or placebo groups. It is triple blind, meaning patients, doctors, and study staff do not know who gets which treatment, and the main goal is to see if the drug is safe while giving early signs of benefit.

The study was first submitted on Mar. 6, 2026, marking the formal start of the clinical path for ALN-2232 in obesity. The latest update on May 12, 2026, confirms the trial is active and still recruiting, so investors should expect safety and early efficacy readouts to follow in later company updates.

For Alnylam (ALNY), this study opens a path into the high-value obesity market now led by GLP-1 players like Eli Lilly and Novo Nordisk. Positive signals could expand ALNY’s story beyond rare disease RNA drugs, support valuation multiples, and improve sentiment, though early-stage risk and strong incumbents mean investors should size positions with care.

The ALN-2232 obesity study is currently ongoing with recent updates posted, and further details are available on the ClinicalTrials portal.

To learn more about ALNY’s potential, visit the Alnylam Pharmaceuticals drug pipeline page.